Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos Inks Target-Discovery Deal with Boehringer Ingelheim

NEW YORK, Jan. 16 (GenomeWeb News) - Galapagos said today that its BioFocus service division will use its siRNA-based gene collection to provide Boehringer Ingelheim with novel drug targets.

 

The three-year deal could be worth more than €2 million ($2.4 million), Galapagos said.

 

Terms of the collaboration call for BioFocus to expand its SilenceSelect siRNA-based gene collection with an additional gene set, develop a dedicated cellular assay in the field of autoimmune disease, and use this assay to run a target-discovery screen, the company said.

 

Galapagos will receive upfront fees, as well as research and development funding, and stands to receive milestone fees when certain drug-discovery criteria are met.

 

Additional terms were not provided.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.